Somite Raised $5.3M in Pre-seed Round to Revolutionize Cell Therapy with AI

Somite Raised $5.3M in Pre-seed Round to Revolutionize Cell Therapy with AI

Somite, a venture-backed company aiming to revolutionize stem cell biology with AI, has announced the successful closing of a $5.3 million pre-seed funding round. Led by prominent Israeli venture fund TechAviv, the round was attended by leading Austin-based VCs Next Coast Ventures, Trust Ventures, Texas Venture Partners, as well as NY-based Lerer Hipio. The funding will fuel continued development of Somite's proprietary AlphaStem AI platform, establish Somite Labs, and advance the first therapeutic asset into Phase 1 clinical trials.

Founded in October 2023, Somite is dedicated to building AI foundation models for scalable production of human tissue for cell therapy. These therapies have enormous potential to treat many diseases that involve the loss or depletion of cell populations, including diabetes, obesity, and muscular dystrophies.

The founding team consists of five distinguished experts in their respective fields: Dr. Micha Breakstone, a seasoned AI entrepreneur who previously sold Chorus.ai for $575 million, serves as CEO; They are joined by Dr. Jonathan Rosenfeld, CTO, who pioneered the AI ​​scaling laws at MIT, along with Boston-based scientists Dr. Oliver Porkey, Dr. Alvin Klein, and Dr. Cliff Tabin, who bring expertise in developmental biology. are cells, and computational biology.

Cell therapy represents a revolutionary approach to medical treatment by replacing missing, damaged, or diseased cells. Despite recent advances in stem cell research, current protocols remain challenging in terms of efficiency, scalability, and robustness. Somite.ai aims to address these challenges by mastering the efficient production of cells derived from somites—a key embryonic structure that gives rise to muscle cells.

Leveraging its expertise, Somite is pioneering the development of a digital twin of the embryo—a computational model that mimics the development and behavior of a real embryo. This digital twin, drawing from data-rich sources such as scRNA-Seq, scATAC-seq, and gene expression databases, uses artificial intelligence to unlock innovative protocols, identify regulators of cell differentiation, and drive rapid optimization cycles. Gives the power of

Somite's proprietary digital twin accelerates protocol iteration and uncovers actionable insights, further enhanced by optimization work done in the Porky laboratory. This approach has led to significant milestones, including accepting the prestigious Blavatnik Harvard Life Labs and securing intellectual property for groundbreaking patents.

About the Author

Leave a Reply